Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

Published:2014-11 Issue:12 Volume:15 Page:1389-1396
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Noh Sung Hoon,Park Sook Ryun,Yang Han-Kwang,Chung Hyun Cheol,Chung Ik-Joo,Kim Sang-Woon,Kim Hyung-Ho,Choi Jin-Hyuk,Kim Hoon-Kyo,Yu Wansik,Lee Jong Inn,Shin Dong Bok,Ji Jiafu,Chen Jen-Shi,Lim Yunni,Ha Stella,Bang Yung-Jue

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification;Kodera;J Am Coll Surg,1988

2. Prognostic significance of the number of positive lymph nodes in gastric carcinoma;Adachi;Br J Surg,1994

3. Gastric Cancer Working Group report;Sasako;Jpn J Clin Oncol,2010

4. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Okines;Ann Oncol,2010

5. Guidelines for the management of oesophageal and gastric cancer;Allum;Gut,2011

Cited by 842 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Useful of proximal gastrectomy with double-tract reconstruction in preventing glucose spikes;Journal of Gastrointestinal Surgery;2024-09

2. Innovative Prediction of VEGF Levels and Prognosis in Gastric Cancer through PET/CT-Based Radiomics;2024-08-27

3. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;LANCET GASTROENTEROL;2024

4. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;The Lancet Gastroenterology & Hepatology;2024-08

5. Acute therapy-related myelodysplastic syndromes following capecitabine and oxaliplatin therapy in gastric malignant tumor: A case report;Medicine;2024-07-26